- Published on
KembaraXtra-Medicine – Autoimmune Polyendocrine Syndromes
Autoimmune polyendocrine syndrome (APS) refers to a group of disorders characterized by autoimmune-mediated functional impairment of multiple endocrine glands occurring in specific patterns. These conditions are also known as autoimmune polyglandular syndrome or autoimmune polyglandular failure and include autoimmune polyendocrine syndrome type 1 (APS-1) and type 2 (APS-2). The ICD-10-CM code for autoimmune polyglandular failure is E31.0.
APS-1 may occur at any stage of life but most commonly presents in early childhood or early adulthood. Clinical expression is highly variable, even among family members. Its estimated prevalence is about 1 in 100,000 in most countries, with much higher rates in genetically isolated populations such as Finland, Sardinia, and Persian Jewish communities. APS-2 is more common, with a prevalence ranging from 1 in 1,000 to 1 in 20,000. It predominantly affects women and usually presents between 20 and 40 years of age. Rare cases of APS-2 have been reported following treatment with immune checkpoint inhibitors.
Genetically, APS-1 is most often a monogenic disorder inherited in an autosomal recessive pattern, although autosomal dominant cases have been reported due to dominant-negative mutations of the AIRE gene. APS-2 has a polygenic inheritance pattern with heterogeneous clinical expression resulting from interactions between multiple genetic loci and environmental factors.
APS-1 is defined by the presence of at least two of three major features: hypoparathyroidism, chronic mucocutaneous candidiasis, and primary adrenal insufficiency. Hypoparathyroidism is the most common endocrine manifestation, while chronic mucocutaneous candidiasis is often the first clinical feature to appear. Primary hypogonadism is also common. Other associated features include enamel hypoplasia, bilateral keratitis, autoimmune hepatitis, pneumonitis, nephritis, and functional asplenia. Most patients present by five years of age, with nonendocrine manifestations often preceding endocrine disease. On average, individuals develop four to five associated disorders, with diabetes mellitus usually occurring later in the disease course.
APS-2 is characterized by the triad of autoimmune adrenal insufficiency, autoimmune thyroid disease, and type 1 diabetes mellitus, with adrenal insufficiency required for diagnosis. It typically presents later than APS-1, most often between 20 and 40 years of age. APS-3 differs in that adrenal insufficiency is absent; patients have autoimmune thyroid disease along with other autoimmune conditions such as type 1 diabetes, atrophic gastritis, pernicious anemia, alopecia, vitiligo, or myasthenia gravis.
Individual endocrine disorders present with characteristic clinical features. Hypocalcemia from primary hypoparathyroidism may cause tetany, perioral paresthesias, prolonged QT interval, basal ganglia calcifications, seizures, and arrhythmias. Autoimmune hypothyroidism commonly presents with fatigue, weight gain, constipation, cold intolerance, menstrual irregularities, and hair or nail changes, with myxedema coma representing the most severe manifestation. Autoimmune adrenal insufficiency may present with weight loss, fatigue, nausea, anorexia, malaise, and skin hyperpigmentation, while adrenal crisis can cause hypotension, nausea, and vomiting. Type 1 diabetes mellitus typically presents with polyuria, polydipsia, and weight loss, with diabetic ketoacidosis being the most life-threatening complication. Hypogonadism may manifest as low libido and fatigue in males or oligomenorrhea in females.
The etiology of APS-1 involves inactivating mutations of the autoimmune regulator (AIRE) gene on chromosome 21, leading to defective negative selection of autoreactive T cells and impaired regulatory T-cell function. APS-2 is associated with mutations in the human leukocyte antigen (HLA) complex on chromosome 6, along with other immune regulatory genes, resulting in lymphocytic infiltration and organ-specific autoimmunity.
Diagnosis is often delayed due to the variable and sequential nature of disease manifestations. Rarely do adrenal, thyroid, and pancreatic endocrine disorders develop simultaneously. Once one autoimmune endocrinopathy is identified, regular screening for additional autoimmune conditions is essential. Hypoparathyroidism is diagnosed by low calcium levels with low or inappropriately normal parathyroid hormone levels, after correcting hypomagnesemia if present. Autoimmune hypothyroidism is diagnosed by elevated thyroid-stimulating hormone levels and may be supported by thyroid autoantibodies. Autoimmune adrenal insufficiency is diagnosed by low cortisol levels or inadequate response to cosyntropin stimulation, with elevated ACTH levels and possible electrolyte abnormalities; anti–21-hydroxylase antibodies may be present. Autoimmune hypogonadism is diagnosed by low sex hormone levels with elevated gonadotropins. Type 1 diabetes mellitus is diagnosed by elevated glucose or hemoglobin A1c levels, with diabetes-related autoantibodies often present.
Acute management focuses on life-threatening complications. Chronic mucocutaneous candidiasis requires antifungal therapy, good oral hygiene, and smoking cessation. Severe hypocalcemia is treated with intravenous calcium followed by oral calcium and calcitriol. Myxedema coma requires intravenous thyroid hormone, glucocorticoids, and intensive supportive care. Diabetic ketoacidosis is managed with intravenous fluids, insulin, and electrolyte correction. Suspected adrenal crisis must be treated immediately with intravenous hydrocortisone and volume resuscitation without waiting for laboratory confirmation.
Chronic management centers on lifelong hormone replacement and surveillance for new autoimmune conditions. Hypoparathyroidism is treated with calcitriol and calcium supplementation, with thiazide diuretics used for hypercalciuria and parathyroid hormone replacement reserved for refractory cases. Autoimmune hypothyroidism is treated with oral levothyroxine, ensuring adrenal insufficiency is excluded or treated first. Primary adrenal insufficiency requires glucocorticoid and mineralocorticoid replacement, sick-day education, emergency hydrocortisone access, and medical alert identification. Type 1 diabetes mellitus requires insulin therapy. Primary hypogonadism is treated with sex hormone replacement appropriate to patient anatomy. In APS-1 patients presenting initially with chronic mucocutaneous candidiasis, regular screening for adrenal insufficiency is recommended.
Because disease components accumulate over time, management should be coordinated by a multidisciplinary team led by an endocrinologist. Patient education is essential so individuals can recognize early symptoms of additional autoimmune conditions. APS is frequently diagnosed late due to its heterogeneous presentation, and once one disorder is identified, systematic screening for associated autoimmune diseases should be initiated. All siblings of patients with APS-1 should undergo genetic testing or regular clinical screening, and long-term follow-up is critical for optimizing outcomes.
Autoimmune polyendocrine syndrome (APS) refers to a group of disorders characterized by autoimmune-mediated functional impairment of multiple endocrine glands occurring in specific patterns. These conditions are also known as autoimmune polyglandular syndrome or autoimmune polyglandular failure and include autoimmune polyendocrine syndrome type 1 (APS-1) and type 2 (APS-2). The ICD-10-CM code for autoimmune polyglandular failure is E31.0.
APS-1 may occur at any stage of life but most commonly presents in early childhood or early adulthood. Clinical expression is highly variable, even among family members. Its estimated prevalence is about 1 in 100,000 in most countries, with much higher rates in genetically isolated populations such as Finland, Sardinia, and Persian Jewish communities. APS-2 is more common, with a prevalence ranging from 1 in 1,000 to 1 in 20,000. It predominantly affects women and usually presents between 20 and 40 years of age. Rare cases of APS-2 have been reported following treatment with immune checkpoint inhibitors.
Genetically, APS-1 is most often a monogenic disorder inherited in an autosomal recessive pattern, although autosomal dominant cases have been reported due to dominant-negative mutations of the AIRE gene. APS-2 has a polygenic inheritance pattern with heterogeneous clinical expression resulting from interactions between multiple genetic loci and environmental factors.
APS-1 is defined by the presence of at least two of three major features: hypoparathyroidism, chronic mucocutaneous candidiasis, and primary adrenal insufficiency. Hypoparathyroidism is the most common endocrine manifestation, while chronic mucocutaneous candidiasis is often the first clinical feature to appear. Primary hypogonadism is also common. Other associated features include enamel hypoplasia, bilateral keratitis, autoimmune hepatitis, pneumonitis, nephritis, and functional asplenia. Most patients present by five years of age, with nonendocrine manifestations often preceding endocrine disease. On average, individuals develop four to five associated disorders, with diabetes mellitus usually occurring later in the disease course.
APS-2 is characterized by the triad of autoimmune adrenal insufficiency, autoimmune thyroid disease, and type 1 diabetes mellitus, with adrenal insufficiency required for diagnosis. It typically presents later than APS-1, most often between 20 and 40 years of age. APS-3 differs in that adrenal insufficiency is absent; patients have autoimmune thyroid disease along with other autoimmune conditions such as type 1 diabetes, atrophic gastritis, pernicious anemia, alopecia, vitiligo, or myasthenia gravis.
Individual endocrine disorders present with characteristic clinical features. Hypocalcemia from primary hypoparathyroidism may cause tetany, perioral paresthesias, prolonged QT interval, basal ganglia calcifications, seizures, and arrhythmias. Autoimmune hypothyroidism commonly presents with fatigue, weight gain, constipation, cold intolerance, menstrual irregularities, and hair or nail changes, with myxedema coma representing the most severe manifestation. Autoimmune adrenal insufficiency may present with weight loss, fatigue, nausea, anorexia, malaise, and skin hyperpigmentation, while adrenal crisis can cause hypotension, nausea, and vomiting. Type 1 diabetes mellitus typically presents with polyuria, polydipsia, and weight loss, with diabetic ketoacidosis being the most life-threatening complication. Hypogonadism may manifest as low libido and fatigue in males or oligomenorrhea in females.
The etiology of APS-1 involves inactivating mutations of the autoimmune regulator (AIRE) gene on chromosome 21, leading to defective negative selection of autoreactive T cells and impaired regulatory T-cell function. APS-2 is associated with mutations in the human leukocyte antigen (HLA) complex on chromosome 6, along with other immune regulatory genes, resulting in lymphocytic infiltration and organ-specific autoimmunity.
Diagnosis is often delayed due to the variable and sequential nature of disease manifestations. Rarely do adrenal, thyroid, and pancreatic endocrine disorders develop simultaneously. Once one autoimmune endocrinopathy is identified, regular screening for additional autoimmune conditions is essential. Hypoparathyroidism is diagnosed by low calcium levels with low or inappropriately normal parathyroid hormone levels, after correcting hypomagnesemia if present. Autoimmune hypothyroidism is diagnosed by elevated thyroid-stimulating hormone levels and may be supported by thyroid autoantibodies. Autoimmune adrenal insufficiency is diagnosed by low cortisol levels or inadequate response to cosyntropin stimulation, with elevated ACTH levels and possible electrolyte abnormalities; anti–21-hydroxylase antibodies may be present. Autoimmune hypogonadism is diagnosed by low sex hormone levels with elevated gonadotropins. Type 1 diabetes mellitus is diagnosed by elevated glucose or hemoglobin A1c levels, with diabetes-related autoantibodies often present.
Acute management focuses on life-threatening complications. Chronic mucocutaneous candidiasis requires antifungal therapy, good oral hygiene, and smoking cessation. Severe hypocalcemia is treated with intravenous calcium followed by oral calcium and calcitriol. Myxedema coma requires intravenous thyroid hormone, glucocorticoids, and intensive supportive care. Diabetic ketoacidosis is managed with intravenous fluids, insulin, and electrolyte correction. Suspected adrenal crisis must be treated immediately with intravenous hydrocortisone and volume resuscitation without waiting for laboratory confirmation.
Chronic management centers on lifelong hormone replacement and surveillance for new autoimmune conditions. Hypoparathyroidism is treated with calcitriol and calcium supplementation, with thiazide diuretics used for hypercalciuria and parathyroid hormone replacement reserved for refractory cases. Autoimmune hypothyroidism is treated with oral levothyroxine, ensuring adrenal insufficiency is excluded or treated first. Primary adrenal insufficiency requires glucocorticoid and mineralocorticoid replacement, sick-day education, emergency hydrocortisone access, and medical alert identification. Type 1 diabetes mellitus requires insulin therapy. Primary hypogonadism is treated with sex hormone replacement appropriate to patient anatomy. In APS-1 patients presenting initially with chronic mucocutaneous candidiasis, regular screening for adrenal insufficiency is recommended.
Because disease components accumulate over time, management should be coordinated by a multidisciplinary team led by an endocrinologist. Patient education is essential so individuals can recognize early symptoms of additional autoimmune conditions. APS is frequently diagnosed late due to its heterogeneous presentation, and once one disorder is identified, systematic screening for associated autoimmune diseases should be initiated. All siblings of patients with APS-1 should undergo genetic testing or regular clinical screening, and long-term follow-up is critical for optimizing outcomes.
0 Comments
